Abstract| Volume 51, SUPPLEMENT 1, S11, March 2015

Download started.


ITOC2 – 030. Identification of the neoantigen Ndufs1-V491A for investigations on immunotherapies in murine tumour models

      This paper is only available as a PDF. To read, Please Download here.
      Solid cancers are highly refractory to conventional therapies and urgently need alternative treatments. We showed in previous work that tumour-directed dendritic cell vaccines (DC) when applied during oncolytic virus-mediated tumour inflammation (referred to as ODC) successfully triggers a CD8 T-cell response against model-antigens in mice.
      The central aim of this study was to identify tumour-associated neoantigens suitable to investigate the efficacy of ODC treatment. Therefore, we performed transcriptomic sequencing and epitope prediction leading to detection of the neoepitope Ndufs1-V491A which is present in the NSCLC cell line CMT64 and the HCC cell line Hepa1.6. Elispot assays showed that intratumoural infection of subcutaneous (s.c.) CMT64-tumours on C57Bl/6 mice with oncolytic adenovirus induced significant T-cell responses against Ndufs1-V491A that were significantly less reactive to the wild type peptide. FACS analyses demonstrated neoepitope-specific T-cell responses after Ndufs1-V491A-directed DC vaccination that were additionally amplified by ODC. This ODC treatment was furthermore capable of inducing neoantigen-specific cytotoxicity as shown by in vivo CTL analyses. Finally, we established an Ndufs1-V491A-specific pentamer that allows functional investigations on Ndufs1-V491A-specific CD8 cells.
      In summary, we established the neoantigen Ndufs1-V491A which is well suited to investigate tumour-directed CD8 T-cells raised by various immunotherapeutic approaches in murine tumour models.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect